

What is claimed is:

1. A vector comprising a nucleotide sequence that encodes a truncated Flk-1, lacking a functional Flk-1 cytoplasmic domain but having a functional Flk-1 extracellular and transmembrane domain, which inhibits the cellular effects of VEGF binding.
2. The vector of claim 1 comprising a nucleotide sequence encoding amino acids 1 through 806 of Flk-1.
3. The vector of claim 1 in which the vector is a retrovirus vector, an adeno-associated viral vector or a herpes viral vector.
4. The vector of claim 3 comprising a nucleotide sequence encoding amino acids 1 through 806 of Flk-1.
5. A cell line that comprises the recombinant vector of claim 1 and expresses truncated Flk-1.
6. A cell line that comprises the recombinant retrovirus vector of claim 3 or 4, wherein said cell line (i) produces infectious retrovirus particles encoding truncated Flk-1 and (ii) expresses truncated Flk-1 encoded by said retrovirus vector.
7. A truncated Flk-1 receptor protein, lacking a functional Flk-1 cytoplasmic domain but having a functional Flk-1 extracellular and transmembrane domain, wherein said protein inhibits the cellular effects of VEGF binding.
8. The truncated Flk-1 receptor protein of claim 7 comprising amino acids 1 through 806 of Flk-1.

9. The truncated Flk-1 receptor protein of claim 7 comprising amino acids 1 through 806 of Flk-1 but lacking the 561 COOH-terminal amino acids of the intracellular kinase domain of Flk-1.